366 related articles for article (PubMed ID: 17236958)
21. Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis.
Ma Y; Zheng C; Feng Y; Xu Q
J Craniofac Surg; 2017 Sep; 28(6):e569-e571. PubMed ID: 28749838
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
Khan M; Zhao Z; Arooj S; Liao G
BMC Cancer; 2021 Feb; 21(1):167. PubMed ID: 33593308
[TBL] [Abstract][Full Text] [Related]
24. [Bevacizumab for the treatment of cerebral radionecrosis].
Gronier S; Bourg V; Frenay M; Cohen M; Mondot L; Thomas P; Lebrun C
Rev Neurol (Paris); 2011 Apr; 167(4):331-6. PubMed ID: 21420137
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
Ziemssen F; Voelker M; Altpeter E; Bartz-Schmidt KU; Gelisken F
Acta Ophthalmol Scand; 2007 Aug; 85(5):579-80. PubMed ID: 17324216
[No Abstract] [Full Text] [Related]
26. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
27. Single-shot bevacizumab for cerebral radiation injury.
Voss M; Wenger KJ; Fokas E; Forster MT; Steinbach JP; Ronellenfitsch MW
BMC Neurol; 2021 Feb; 21(1):77. PubMed ID: 33596839
[TBL] [Abstract][Full Text] [Related]
28. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
29. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.
Wang Y; Wang E; Pan L; Dai J; Zhang N; Wang X; Liu X; Mei G; Sheng X
J Neurooncol; 2014 Sep; 119(2):369-76. PubMed ID: 24879376
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab alleviates radiation-induced brain necrosis: A report of four cases.
Xiang-Pan L; Yuxin C; Xiao-Fei W; Na L; Tang-Peng X; Xiao-Tao X; Chang-Li R; Wei-Guo H; Qi-Bin S
J Cancer Res Ther; 2015; 11(2):485-7. PubMed ID: 26148625
[TBL] [Abstract][Full Text] [Related]
31. An analysis of radiation necrosis of the central nervous system treated with bevacizumab.
Tye K; Engelhard HH; Slavin KV; Nicholas MK; Chmura SJ; Kwok Y; Ho DS; Weichselbaum RR; Koshy M
J Neurooncol; 2014 Apr; 117(2):321-7. PubMed ID: 24504500
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.
Yonezawa S; Miwa K; Shinoda J; Nomura Y; Asano Y; Nakayama N; Ohe N; Yano H; Iwama T
J Neurooncol; 2014 Aug; 119(1):101-9. PubMed ID: 24789256
[TBL] [Abstract][Full Text] [Related]
33. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab.
Weiss K; Steinbrugger I; Weger M; Ardjomand N; Maier R; Wegscheider BJ; Wedrich A; El-Shabrawi Y
Eye (Lond); 2009 Sep; 23(9):1812-8. PubMed ID: 19169227
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET.
Furuse M; Nonoguchi N; Kawabata S; Yoritsune E; Takahashi M; Inomata T; Kuroiwa T; Miyatake S
Jpn J Clin Oncol; 2013 Mar; 43(3):337-41. PubMed ID: 23303838
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Relief of Cerebral Radiation Necrosis Treated with Low-Dose Bevacizumab - a Report of 2 Cases.
Hu Q; Zhao J; Xu J; Zhou X; Shui Y; Shen L; Wei Q
Oncol Res Treat; 2017; 40(3):133-137. PubMed ID: 28231593
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
